On Path to First-in-Human Study, NurExone Engages Prominent
TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the ...
Read moreTORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the ...
Read moreKYN-5356 is an innovative, first-in-class small molecule that targets KAT-II, a key enzyme in the kynurenine pathway Topline results are ...
Read morePhase 1 clinical trial will enroll 88 healthy volunteers in the United KingdomETH47 is a first-in-class, broadly protective antiviral candidate ...
Read more-- Positive trends continue as more patients receive treatment with WU-CART-007 in this study exploring the drug’s potential in improving ...
Read moreOutstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.